148 related articles for article (PubMed ID: 21386819)
1. Targeted therapies: bevacizumab--has it reached its final resting place?
Kerr DJ; Young AM
Nat Rev Clin Oncol; 2011 Mar; 8(4):195-6. PubMed ID: 21386819
[No Abstract] [Full Text] [Related]
2. [Bevacizumab and radiotherapy].
Blanchard P; Besse B; Deutsch E
Rev Mal Respir; 2008 Dec; 25(10):1319-21. PubMed ID: 19107021
[No Abstract] [Full Text] [Related]
3. Bevacizumab: one treatment for all the seasons?
Gelibter AJ; Di Segni S; Zeuli M; Cognetti F
J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430
[No Abstract] [Full Text] [Related]
4. Targeting angiogenesis in an age of personalized medicine.
Kota GK; Gupta P; Conyers JM; Mintz A
Cancer Biol Ther; 2010 Nov; 10(9):874-7. PubMed ID: 21057212
[No Abstract] [Full Text] [Related]
5. Bevacizumab and surgery: what is the real risk?
Cohen R; Stebbing J; Windsor A
Future Oncol; 2009 Sep; 5(7):915-7. PubMed ID: 19792957
[No Abstract] [Full Text] [Related]
6. Cancer: The nuances of therapy.
Ellis LM; Reardon DA
Nature; 2009 Mar; 458(7236):290-2. PubMed ID: 19295595
[No Abstract] [Full Text] [Related]
7. Bevacizumab.
Ellis LM
Nat Rev Drug Discov; 2005 May; Suppl():S8-9. PubMed ID: 15962523
[TBL] [Abstract][Full Text] [Related]
8. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions.
Ocaña A; Amir E; Vera F; Eisenhauer EA; Tannock IF
J Clin Oncol; 2011 Jan; 29(3):254-6. PubMed ID: 21149670
[No Abstract] [Full Text] [Related]
9. Circulating endothelial cells as biomarkers for patients receiving bevacizumab.
Bertolini F; Mancuso P; Shaked Y
Lancet Oncol; 2011 Mar; 12(3):217-8. PubMed ID: 21376289
[No Abstract] [Full Text] [Related]
10. Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
Mayer EL; Lin NU; Burstein HJ
J Natl Compr Canc Netw; 2007 Mar; 5(3):314-23. PubMed ID: 17439759
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in adult malignant brainstem gliomas.
Raza S; Donach M
J Neurooncol; 2009 Nov; 95(2):299-300. PubMed ID: 19506812
[No Abstract] [Full Text] [Related]
12. Bevacizumab.
Kazazi-Hyseni F; Beijnen JH; Schellens JH
Oncologist; 2010; 15(8):819-25. PubMed ID: 20688807
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies: Goldie-Coldman and bevacizumab beyond disease progression.
Giantonio BJ
Nat Rev Clin Oncol; 2009 Jun; 6(6):311-2. PubMed ID: 19483736
[TBL] [Abstract][Full Text] [Related]
14. Promising early results for immunotherapy-antiangiogenesis combination.
Garber K
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
[No Abstract] [Full Text] [Related]
15. [Anti-angiogenetic agents for solid tumors].
Blay JY
Rev Med Interne; 2007 Jun; 28 Suppl 1():S7-8. PubMed ID: 17482319
[No Abstract] [Full Text] [Related]
16. Bevacizumab for retinopathy of prematurity.
Gilbert CE; Zin A; Darlow B
N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
[No Abstract] [Full Text] [Related]
17. Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by Xavier Pivot.
Pivot X
Drugs; 2007; 67(12):1800-1. PubMed ID: 17683176
[No Abstract] [Full Text] [Related]
18. Biomarkers in breast cancer.
McArthur HL; Dickler MN
Cancer Biol Ther; 2008 Jan; 7(1):21-2. PubMed ID: 18347421
[No Abstract] [Full Text] [Related]
19. Bevacizumab for retinopathy of prematurity.
Lim LS; Mitchell P; Wong TY
N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
[No Abstract] [Full Text] [Related]
20. Taming vessels to treat cancer.
Jain RK
Sci Am; 2008 Jan; 298(1):56-63. PubMed ID: 18225696
[No Abstract] [Full Text] [Related]
[Next] [New Search]
